User profiles for KOICHI MITSUYA

Koichi Mitsuya

Staff, Neurosurgery, Shizuoka Cancer center
Verified email at scchr.jp
Cited by 2057

Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery

K Mitsuya, Y Nakasu, S Horiguchi, H Harada… - Journal of neuro …, 2010 - Springer
After stereotactic radiosurgery (SRS) for brain metastases, delayed radiation effects with
mass effect may occur from several months to years later, when tumors may also recur. …

[HTML][HTML] Metastatic skull tumors: MRI features and a new conventional classification

K Mitsuya, Y Nakasu, S Horiguchi, H Harada… - Journal of neuro …, 2011 - Springer
Skull metastases are malignant bone tumors which are increasing in incidence. The
objectives of this study were to characterize the MR imaging features, locations, and extent of …

[HTML][HTML] α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

…, T Ashizawa, M Yagoto, Y Abe, K Mitsuya… - BMC cancer, 2012 - Springer
Background High-grade gliomas including glioblastoma multiforme (GBM) are among the
most malignant and aggressive of tumors, and have a very poor prognosis despite a …

[HTML][HTML] Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma

…, T Oishi, R Watanabe, K Mitsuya… - International …, 2013 - spandidos-publications.com
Signal transducer and activator of transcription (STAT) 3, a member of a family of DNA-binding
molecules, is a potential target in the treatment of cancer. The highly phosphorylated …

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure

…, H Kenmotsu, H Murakami, H Harada, K Mitsuya… - Lung Cancer, 2011 - Elsevier
INTRODUCTION: Based on previous reports, patients who experience isolated central nervous
system (CNS) failure may not have systemic acquired resistance to EGFR-TKI therapy. …

Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse

…, C Maeda, H Miyata, T Sugino, K Mitsuya… - Clinical Cancer …, 2017 - AACR
Purpose: Humanized mouse models using NOD/Shi-scid-IL2rγ null (NOG) and NOD/LtSz-scid
IL2rγ null (NSG) mouse are associated with several limitations, such as long incubation …

Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: A systematic review and meta-analysis

…, M Yamazaki, A Notsu, K Mitsuya… - Neuro-oncology …, 2023 - academic.oup.com
Background Cerebrospinal fluid (CSF) cytology remains the gold standard approach for
diagnosing of leptomeningeal metastases (LM), but has clinical problems due to its low …

Leptomeningeal metastasis in ER+ HER2-advanced breast cancer patients: a review of the cases in a single institute over a 15-year period

J Watanabe, K Mitsuya, S Nakamoto, H Harada… - Breast Cancer Research …, 2021 - Springer
Purpose While leptomeningeal metastasis (LM) from estrogen receptor-positive, HER2-negative
advanced breast cancer (ER + HER2-ABC) has a poor prognosis, the details of ER + …

Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis

K Mitsuya, Y Nakasu, T Kurakane, N Hayashi… - Journal of …, 2017 - thejns.org
OBJECTIVE The median postoperative survival duration of patients with brain metastases
who undergo tumor resection is 12 months. Most of these patients die of systemic metastases …

[HTML][HTML] Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas

S Deguchi, T Oishi, K Mitsuya, Y Kakuda, M Endo… - Scientific reports, 2020 - nature.com
T2-FLAIR mismatch sign is known as a highly specific imaging marker of IDH-mutant
astrocytomas. This study was intended to clarify what the T2-FLAIR mismatch sign represents by …